NanoViricides is trading at $1.37, up 6.07% in pre-market, with no identified company-specific catalyst for the move.
- No fresh company-specific announcement explaining the November 6 move appeared in search results; the latest identified company update was its October 27 report that the Phase IIA Ebola trial was progressing.
- Reuters reported a sharp November 5 technology-led selloff tied to AI spending and policy concerns, followed by higher Nasdaq futures on November 6. That does not establish a cause for NanoViricides’ pre-market rise.